BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2026 RESULTS, RAISES GUIDANCE
Bausch Health posted Q3 2026 revenue of $2.94 billion, up 10% reported and 8% organic, with GAAP EPS of $1.15 versus $0.48 a year ago and adjusted EPS of $1.77, up 53%. Adjusted EBITDA attributable to Bausch Health rose 32% to $1,305 million, and cash from operations more than doubled to $813 million; the company cut net debt by more than $500 million in the quarter. Bausch Health excluding Bausch + Lomb delivered its fourteenth consecutive quarter of YoY revenue and Adjusted EBITDA growth, with quarterly ex-B+L Adjusted EBITDA exceeding $1 billion for the first time, and management raised full-year 2026 guidance across revenue, Adjusted EBITDA, and adjusted cash flows.
Key figures
- Eps
- 1.15
- Revenue
- 2941000000
- Guidance
- BHC (excl. B+L) FY2026 revenue raised to $5.525-$5.625B with 7-9% revenue growth; consolidated revenue $10.975-$11.175B; consolidated Adjusted EBITDA $4.315-$4.415B (12-14% growth); BHC (excl. B+L) Adjusted Cash Flows from Operations $1.600-$1.675B
- Revenue Yoy
- 10%
- Adjusted eps
- 1.77
- Adjusted ebitda
- 1305000000
- Gaap net income
- 436000000
- Operating income
- 983000000
- Net debt reduction
- more than $500 million in the quarter
- Adjusted ebitda yoy
- 32%
- Adjusted eps growth
- 53%
- Adjusted net income
- 673000000
- Cash and equivalents
- 2485000000
- Cash from operations
- 813000000
- Buyback authorization
- 50000000
- Salix segment revenue
- 831000000
- Xifaxan revenue growth
- 16%
- Adjusted eps prior year
- 1.16
- Bausch and lomb segment revenue
- 1375000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.